Bioconjugate Chemistry
ARTICLE
histogram, UV/visible spectrum of synthesized gold nanoparti-
cles and images of in vitro assays. This material is available free of
(15) Belvisi, L., Bernardi, A., Checchia, A., Manzoni, L., Potenza, D.,
Scolastico, C., Castorina, M., Cupelli, A., Giannini, G., Carminati, P., and
Pisano, C. (2001) Potent integrin antagonist from a small library of
RGD-including cyclic pseudopeptides. Org. Lett. 1001–1004.
(16) Belvisi, L., Riccioni, T., Marcellini, M., Chiarucci, I., Efrati, D.,
Vesci, L., Potenza, D., Scolastico, C., Manzoni, L., Lombardo, K., Stasi,
M. A., Nico, B., Ribatti, D., Presta, M., Carminati, P., and Pisano, C.
(2005) Biological and molecular properties of a new Rvβ3/Rvβ5
integrin antagonist. Mol. Cancer Therapeut. 4, 1670–1680.
(17) Manzoni, L., Belvisi, L., Arosio, D., Civera, M., Pilkington-
Miksa, M., Potenza, D., Caprini, A., Araldi, E. M. V., Monferini, E.,
Mancino, M., Podestꢀa, F., and Scolastico, C. (2009) Cyclic RGD-
containing functionalized azabicycloalkane peptides as potent integrin
antagonists for tumor targeting. ChemMedChem 4, 615–632.
(18) Arosio, D., Manzoni, L., Araldi, E. M. V., Caprini, A., Monferini,
E., and Scolastico, C. (2009) Functionalized cyclic RGD peptidomi-
metics: conjugable ligands for RVβ3 receptor imaging. Bioconjugate
Chem. 20, 1611–1617.
’ AUTHOR INFORMATION
Corresponding Author
*Corresponding author. Tel.: þ39 02 50320907, Fax: þ39 02
50320945, e-mail: daniela.arosio@istm.cnr.it.
’ ACKNOWLEDGMENT
The authors thank CNR and Comune di Milano (Con-
venzione 55/2008) for financial support and Comune di Milano
(Convenzione 55/2008) for the PhD Fellowship to Elena Araldi
(Doctorate School of Molecular Medicine, University of Milan).
The authors thank Dr. Umberto Fascio and Dr. Nadia Santo of
CIMA (Centro Interdipartimentale di Microscopia Avanzata) of
the University of Milan for confocal analysis and for TEM
analysis, respectively, and Claudio Arosio for the help in devel-
oping the algorithm for automatic TEM micrograph analysis.
(19) Thumshirn, G., Hersel, U., Goodman, S., and Kessler, H.
(2003) Multimeric cyclic RGD peptides as potentials tools for tumor
targeting: solid-phase peptide synthesis and chemoselective oxime
ligation. Chem.—Eur. J. 9, 2717–2725.
(20) Dijkgraar, I., Kruijtzer, J. A. W., Liu, S., Soede, A. C., Oyen,
W. J. G., Corstens, F. H. M., Liskamp, R. M. J., and Boerman, O. C.
(2007) Improved targeting of the Rvβ3 integrin by multimerisation of
RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 34, 267–273.
(21) Dijkgraar, I., Rijnders, A. Y., Soede, A., Dechesne, A. C., van
Esse, G. W., Brouwer, A. J., Corstens, F. H. M., Boerman, O. C., Rijkers,
D. T. S., and Liskamp, R. M. J. (2007) Synthesis of DOTA-conjugated
multivalent cyclic-RGD peptide dendrimers via 1.3-dipolar cycloaddi-
tion and their biological evaluation: implications for tumor targeting and
tumor imaging purposes. Org. Biomol. Chem. 5, 935–944.
(22) Dijkgraar, I., Liu, S., Kruijtzer, J. A. W., Soede, A. C., Oyen,
W. J. G., Liskamp, R. M. J., Corstens, F. H. M., and Boerman, O. C.
(2007) Effects of linker variation on the in vitro and in vivo character-
istics of an 111In-labeled RGD peptide. Nucl. Med. Biol. 34, 29–35.
(23) Cheng, Z., Wu, Y., Xiong, Z., Gambhir, S. S., and Chen, X.
(2005) Near-infrared fluorescent RGD for optical imaging of integrin
Rvβ3 expression in living mice. Bioconjugate Chem. 16, 1433–1441.
(24) Li, Z., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., and Chen, X.
(2007) 64Cu-labeled tetrameric and octameric RGD peptides for small-
animal PET of tumor Rvβ3 integrin expression. J. Nucl. Med. 48,
1162–1171.
(25) Shukla, R., Thomas, T. P., Peters, J., Kotlyar, A., Myc, A., and
Baker, J. R. J. Tumor angiogenic vasculature targeting with PAMAM
dendrimer-RGD conjugates. Chem. Commun. 5739ꢀ5741.
(26) Liu, S. (2006) Radiolabeled multimeric cyclic RGD peptides as
integrin Rvβ3 targeted radiotracers for tumor imaging. Mol. Pharmaceu-
tics 3, 472–487and reference therein.
(27) Hersel, U., Dahmen, C., and Kessler, H. (2003) RGD modified
polymers: biomaterials for stimulated cell adhesion and beyond. Bioma-
terials 24, 4385–4415.
(28) Lieb, E., Hacker, M., Tessmar, J., Kunz-Schughart, L. A., Fiedler,
J., Dahmen, C., Hersel, U., Kessler, H., Schulz, M. B., and G€opferich, A.
(2005) Mediating specific cell adhesion to low-adhesive diblok copoly-
mers by instant modification with cyclic RGD peptides. Biomaterials
26, 2333–2341.
(29) Zluza, E., van der Schaft, D. W. J., Hautvast, P. A. I., Mulder,
W. J. M., Mayo, K. H., Griffioen, A. W., Strijkers, G. J., and Nicolay, K.
(2010) Synergistic targeting of Rvβ3 integrin and galectin-1 with
heteromultivalent paramagnetic liposomes for combined MR imaging
and treatment of angiogenesis. Nano lett. 10, 52–58.
(30) Garanger, E., Boturyn, D., Renaudet, O., Defrancq, E., and
Dumy, P. (2006) Chemoselectively addressable template: a valuable tool
fort he engineering of molecular conjugates. J. Org. Chem. 71, 2402–2410.
(31) Boisselier, E., and Astruc, D. (2009) Gold nanoparticles:
preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc.
Rev. 38, 1759–1782.
’ REFERENCES
(1) Giancotti, F., and Ruoslahti, E. (1999) Integrin signaling. Science
285, 1028–1032.
(2) Horton, M. A. (1997) The alphaV beta3 integrin vitronectin
receptor. Int. J. Biochem. Cell Biol. 29, 721–725.
(3) Arnaout, M. A., Goodman, S. L., and Xiong, J. P. (2002) Coming
togrips withintegrinbinding toligands. Curr. Opin. Cell. Biol. 14, 641–651.
(4) Brooks, P. C., Clark, R. A., and Cheresh, D. A. (1994) Require-
ment of vascular integrin alphav beta3 for angiogenesis. Science
264, 569–571.
(5) Costouros, N. G., Diehn, F. E., and Libutti, S. K. (2002)
Molecular imaging of tumor angiogenesis. J. Cell Biochem. Suppl.
39, 72–78.
(6) Desgrosselier, J. S., and Cheresh, D. A. (2010) Integrins in
cancer: biological implications and therapeutic opportunities. Nat. Rev.
Cancer 10, 9–22.
(7) Ding, Q., Stewart, J., Olman, M. A., Klobe, M. R., and Gladson,
C. L. (2003) The pattern of enhancement of Src kinase activity on
platelet-derived growth factor stimulation of glioblastoma cells is
affected by the integrin engaged. J. Biol. Chem. 278, 39882–39891.
(8) Kuphal, S., Bauer, R., and Bosserhoff, A.-K. (2005) Integrin
signaling in malignant melanoma. Cancer Metastasis Rev. 24, 195–
222.
(9) Beck, V., Herold, H., Benge, A., Luber, B., Hutzler, P., Tschesche,
H., Kessler, H., Schmitt, M., Geppert, H. G., and Reuning, U. (2005)
ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian
cancer cell adhesion and motility in an RGD-dependent fashion. Int. J.
Biochem. Cell Biol. 37, 590–603.
(10) Chen, X., Park, R., Tohme, M., Shahinian, A. H., Bading, J. R,
and Conti, P. S. (2004) MicroPET and autoradiographic imaging of
breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled
RGD peptide. Bioconjugate Chem. 15, 41–49.
(11) D’Andrea, L. D., Del Gatto, A., Pedone, C., and Benedetti, E.
(2006) Peptide-based molecules in angiogenesis. Chem. Biol. Drug Des.
67, 115–126.
(12) Haubner, R., Gratias, R., Diefenbach, B., Goodman, S. L.,
Jonczyk, A., and Kessler, H. (1996) Structural and functional aspects
of RGD-containing cyclic pentapeptides as highly potent and selective
integrin alphavbeta3 antagonists. J. Am. Chem. Soc. 118, 7461–7472.
(13) Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E.,
Holzemann, G., Jonczyk, A., Goodmann, S. L., and Kessler, H. (1999)
N-Methylated cyclic RGD peptides as highly active and selective Rvβ3
integrin antagonist. J. Med. Chem. 42, 3033–3040.
(14) Smith, J. W. (2003) Cilengitide Merck. Curr. Opin. Invest. Drugs
4, 741–745.
671
dx.doi.org/10.1021/bc100448r |Bioconjugate Chem. 2011, 22, 664–672